These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 9440473

  • 1. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking.
    Wasada T, Kawahara R, Katsumori K, Naruse M, Omori Y.
    Metabolism; 1998 Jan; 47(1):27-30. PubMed ID: 9440473
    [Abstract] [Full Text] [Related]

  • 2. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition.
    Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP, EUCLID Study Group.
    Diabet Med; 2001 Apr; 18(4):288-94. PubMed ID: 11437859
    [Abstract] [Full Text] [Related]

  • 3. Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy.
    Shimada K, Baba T, Neugebauer S, Onozaki A, Yamada D, Midorikawa S, Sato W, Watanabe T.
    J Diabetes Complications; 2002 Apr; 16(6):386-90. PubMed ID: 12477622
    [Abstract] [Full Text] [Related]

  • 4. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy.
    Hovind P, Tarnow L, Oestergaard PB, Parving HH.
    Kidney Int Suppl; 2000 Apr; 75():S56-61. PubMed ID: 10828763
    [Abstract] [Full Text] [Related]

  • 5. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy.
    Parving HH, Nielsen FS, Bang LE, Smidt UM, Svendsen TL, Chen JW, Gall MA, Rossing P.
    Diabetologia; 1996 Dec; 39(12):1590-7. PubMed ID: 8960847
    [Abstract] [Full Text] [Related]

  • 6. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.
    Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY.
    Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852
    [Abstract] [Full Text] [Related]

  • 7. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study.
    Hernández C, Burgos R, Cantón A, García-Arumí J, Segura RM, Simó R.
    Diabetes Care; 2001 Mar; 24(3):516-21. PubMed ID: 11289478
    [Abstract] [Full Text] [Related]

  • 8. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications.
    Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, Cuccurullo F, Morgese G, Verrotti A.
    Diabet Med; 2000 Sep; 17(9):650-6. PubMed ID: 11051284
    [Abstract] [Full Text] [Related]

  • 9. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy.
    Burgos R, Simó R, Audí L, Mateo C, Mesa J, García-Ramírez M, Carrascosa A.
    Diabetologia; 1997 Sep; 40(9):1107-9. PubMed ID: 9300249
    [Abstract] [Full Text] [Related]

  • 10. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
    Kim NH, Kim KB, Kim DL, Kim SG, Choi KM, Baik SH, Choi DS, Kang YS, Han SY, Han KH, Ji YH, Cha DR.
    Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937
    [Abstract] [Full Text] [Related]

  • 11. Microvascular permeability is increased in both types of diabetes and correlates differentially with serum levels of insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF).
    Brausewetter F, Jehle PM, Jung MF, Boehm BO, Brueckel J, Hombach V, Osterhues HH.
    Horm Metab Res; 2001 Dec; 33(12):713-20. PubMed ID: 11753756
    [Abstract] [Full Text] [Related]

  • 12. Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus.
    Malamitsi-Puchner A, Sarandakou A, Tziotis J, Dafogianni C, Bartsocas CS.
    Pediatr Res; 1998 Dec; 44(6):873-5. PubMed ID: 9853920
    [Abstract] [Full Text] [Related]

  • 13. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?
    Chico A, Pérez A, Córdoba A, Arcelús R, Carreras G, de Leiva A, González-Sastre F, Blanco-Vaca F.
    Diabetologia; 1998 Jun; 41(6):684-93. PubMed ID: 9662051
    [Abstract] [Full Text] [Related]

  • 14. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy.
    Chen J, Gall MA, Yokoyama H, Jensen JS, Deckert M, Parving HH.
    Diabetes Care; 1996 Feb; 19(2):130-4. PubMed ID: 8718432
    [Abstract] [Full Text] [Related]

  • 15. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients.
    Wirta OR, Pasternack AI, Mustonen JT, Koivula TA, Harmoinen A.
    Nephrol Dial Transplant; 1996 Mar; 11(3):449-56. PubMed ID: 8671814
    [Abstract] [Full Text] [Related]

  • 16. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.
    Simó R, Lecube A, Segura RM, García Arumí J, Hernández C.
    Am J Ophthalmol; 2002 Sep; 134(3):376-82. PubMed ID: 12208249
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.
    Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, Jinno K, Kotani Y.
    Eur J Cancer; 1998 Dec; 34(13):2041-5. PubMed ID: 10070308
    [Abstract] [Full Text] [Related]

  • 18. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor.
    Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J.
    Arch Dermatol; 2002 Jun; 138(6):791-6. PubMed ID: 12056961
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.
    Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY.
    Clin Sci (Lond); 2002 Feb; 102(2):187-94. PubMed ID: 11834138
    [Abstract] [Full Text] [Related]

  • 20. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.
    Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R.
    Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.